Evidence map›Paper›PMID 37201956›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2023

Chiara Favaretto, Pascal V Grundler, Zeynep Talip, Stefan Landolt, Lebogang Sepini, Ulli Köster, Cristina Müller, Roger Schibli, Susanne Geistlich, Nicholas P van der Meulen

Open access · hybridAbstract read
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.6field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Fully GMP-complient radiosynthesis of [EJNMMI radiopharmacy and chemistry · 2026
    Article
  2. Practical Aspects ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 3 countries.

Chiara FavarettoCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Pascal V GrundlerCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Zeynep TalipCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Stefan LandoltCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Lebogang SepiniRadiochemistry, South African Nuclear Energy Corp., Brits, South Africa.
Ulli KösterInstitut Laue-Langevin, Grenoble, France; and.
Cristina MüllerCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Roger SchibliCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Susanne GeistlichCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland.
Nicholas P van der MeulenCenter for Radiopharmaceutical Sciences, ETH-Paul Scherrer Institute, Villigen-PSI, Switzerland; nick.vandermeulen@psi.ch.
Paul Scherrer Institute · CHETH Zurich · CHInstitut Laue-Langevin · FRSouth African Nuclear Energy Corporation (South Africa) · ZA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

NeoplasmsRadiopharmaceuticalsHumansIsotope LabelingOctreotideRadioisotopesEdotreotideOctreotideRadioisotopesRadiopharmaceuticals161TbautomatedDOTATOCGMP compliantspecifications

Identifiers

PMID37201956
PMCPMC10315698
OpenAlexW4377019970

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.